Business
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare
VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access barriersVERKAZIA is indicated for the treatment of all forms of vernal keratoconjunctivitis (VKC), a serious allergic eye disease that primarily affects children and may lead to sight-threatening conditions if left untreated or undertreatedVERKAZIA is a calcineurin inhibitor immunomodulator that targets the un
About this update from Harrow, Inc.
NASHVILLE, Tenn., June 10, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the re-launch of VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1%, a prescription therapy indicated for the treatment of vernal keratoconjunctivitis (VKC), a serious allergic eye disease that primarily affects children. “The re-launch of VERKAZIA underscores our commitment to advancing care in underserved ophthalmic conditions,” said Mark L. Baum, Chief Executive Officer of Harrow. “As outlined in our recent Letter to Stockholders, VERKAZIA is the second of three priority products within our portfolio that we are actively executing against. VKC is a clinically significant, yet highly underdiagnosed disease, affecting a vulnerable patient population, where the central challenge has not been clinical efficacy, but consistent access to therapy. Our focus with this re-launch is straightforward: ensure dependable supply, remove access barriers, and enable physicians and patients to reliably obtain this important, evidence-based, and, most importantly, steroid-sparing treatment, for long-term disease management.” “Vernal keratoconjunctivitis is more than a seasonal allergy—it is a chronic inflammatory disease that can meaningfully disrupt a child’s daily life and long-term ocular health,” said Dr. Angela Zhu, M.D., Pediatric Ophthalmologist at Bascom Palmer Eye Institute. “Targeted therapies like VERKAZIA that address the underlying immune response are essential to improving both symptom control and disease trajectory.” “There remains a substantial need for effective, long-term VKC treatment options, particularly those that reduce steroid exposure,” said Dr. Elsa Sheerer, OD., Pediatric Optometrist at NYC Health + Hospitals. “The availability of a targeted cyclosporine formulation is an important advancement for clinicians managing this complex disease.” VKC is a chronic, potentially sight-threatening condition perpetuated by significant ocular inflammation, often resulting in severe itching, pain, photophobia, and, in some cases, corneal damage. The disease typically begins in early childhood and may persist for years—often through adolescence—with seasonal exacerbations and, in some cases, continuation into adulthood. VKC has been shown to significantly impact quality of life, affecting sch...